The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

In today’s ACT Brief, we cover how AI is being deployed to optimize global trial design, why ESG performance is emerging as a core vendor qualification signal, and how sites are becoming more ...

Clinical trials often suffer from a lack of participant diversity, resulting in findings that may not fully represent the eventual treated patient population. This issue has improved only modestly in ...

TORONTO, April 3, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming ...

Speakers at the 2024 World Conference on Lung Cancer discussed the considerations that must go into designing and performing clinical trials in the early-stage lung cancer space, ranging from ...

GSK and Genomics plc will collaborate on a new precision medicine initiative that assesses how genetic data can be used in clinical trial design, Genomics announced April 30. The project will look at ...

Raja Shankar, VP of machine learning at IQVIA, discusses which AI capabilities sponsors are most likely to adopt first to ...

Note: This is the third article of a three-part series. Real-world evidence (RWE) plays a crucial role in supporting the benefits of one drug over another in debates that play out on the boards and ...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...